IL6 and metabolic syndrome: No differences were observed regarding clinical characteristics of MetS in the group treated with Lactobacillus reutri V3401; however, changes in inflammatory biomarkers, anthropometric measurements, and microbiome composition were reported: reduction in IL-6 and VCAM-1 levels, improvement in anthropometric parameters, and increased proportion of Verrucomicrobia phylum [255].